Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Available forms Oral capsules or tablets the most common format for wellness protocols Topical cream or gel may offer transdermal delivery Powder form for compounding allows flexible dosing by qualified pharmacies Subcutaneous injection used in some clinical settings under physician supervision General dosage reference (investigational) Due to Dihexas extraordinary potency and the theoretical concern that excessive HGF/c-Met activation could promote unwanted cellular growth in susceptible individuals conservative dosing and careful medical supervision are strongly emphasized by experienced practitioners
Key mechanistic observations from laboratory studies: VEGF upregulation: BPC-157 is thought to upregulate VEGF expression
As of September 2023 it is on the FDA Category 2 list of bulk drug substances that may not be compounded, and a PCAC review is scheduled for July 2026 under the name Emideltide
Control subjects had no RT-qPCR detectable SARS-CoV-2 in their oropharynx and nasopharynx and no antibodies against the virus in their blood
